Screener / SEC EDGAR /CIK 0001520262 /10-K filed Feb 25, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Alkermes plc. ALKS

The following discussion contains forward-looking statements. 10-K, Item 1

Headquarters
Dublin 4, L2
CEO
Richard F. Pops
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $1.5B through the costs to a net profit of $241.7M · income statement of the 10-K

17% operating margin
Revenue to Gross profit: $1.3BRevenue to Cost of revenue: $196.5MGross profit to Operating profit: $254.0MGross profit to Operating expenses: $1.0BOperating profit to Net profit: $204.2MOperating profit to Tax: $49.8MOther income to Net profit: $37.5MOperating expenses to R&D: $324.0MOperating expenses to SG&A: $701.5M Revenue: $1.5B REVENUE $1.5B −5% Y/Y Gross profit: $1.3B · 87% margin GROSS PROFIT $1.3B 87% margin Cost of revenue: $196.5M · 13% of revenue COST OF REVENUE $196.5M 13% of revenue Operating profit: $254.0M · 17% margin OPERATING PROFIT $254.0M 17% margin · −40% Y/Y Other income: $37.5M · 3% of revenue OTHER INCOME $37.5M 3% of revenue Operating expenses: $1.0B · 69% of revenue OPERATING EXPENSES $1.0B 69% of revenue Net profit: $241.7M · 16% margin NET PROFIT $241.7M 16% margin · −34% Y/Y Tax: $49.8M · 3% of revenue TAX $49.8M 3% of revenue R&D: $324.0M · 22% of revenue R&D $324.0M 22% of revenue SG&A: $701.5M · 48% of revenue SG&A $701.5M 48% of revenue
Gross profit $1.3B 87% margin
Operating profit $254.0M 17% margin · −40% Y/Y
Net profit $241.7M 16% margin · −34% Y/Y
The full income statement, year by year

ALKS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -5.2%, above 5% of 154 peers (their median 10.5%) REVENUE GROWTH -5.2% · above 5% Gross margin: 82.9%, above 86% of 107 peers (their median 63.4%) GROSS MARGIN 82.9% · above 86% Operating margin: 3.7%, above 38% of 138 peers (their median 10.2%) OPERATING MARGIN 3.7% · above 38% Net margin: -0.0%, above 30% of 153 peers (their median 6.8%) NET MARGIN -0.0% · above 30% FCF margin: 13.0%, above 58% of 144 peers (their median 9.9%) FCF MARGIN 13.0% · above 58% Return on capital: 6.2%, above 27% of 89 peers (their median 9.2%) RETURN ON CAPITAL 6.2% · above 27%
ALKS Peer median Below the median

What changed

23 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 12, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +7.5% ($182.9M to $196.6M) vs revenue -5.2% ($1.6B to $1.5B), +12.8 pts apart
  • Receivables -13.1% ($384.5M to $334.0M) vs revenue -5.2% ($1.6B to $1.5B), -7.9 pts apart
9 more checks with nothing to note
  • Cash from operations $520.8M vs net income $241.7M (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Rebate Accruals - Medicaid Drug Rebate Program
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

23 paragraphs in Risk Factors that were not in the 10-K filed Feb 12, 2025. Quoted as filed.

All 23 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
    Additionally, the OBBBA, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program and the enhanced PPACA subsidies expired as of December 31, 2025. Such reductions and loss of subsidies are expected to decrease the number of individuals enrolled in Medicaid over time and reduce the services…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
    We may fail to realize some or all of the anticipated benefits and synergies of the Avadel Acquisition or to successfully integrate Avadel’s business, which could adversely affect our business and financial condition and the price of our ordinary shares. We completed the Avadel Acquisition successfully in February 2026. We are in the…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
    LUMRYZ is a controlled substance subject to U.S. federal and state-controlled substance laws and regulations, and any failure to comply with these laws and regulations, or the cost of compliance with these laws and regulations, could materially adversely affect our business, financial condition, cash flows and results of operations.…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
    In April 2025, Mural announced its intent to discontinue all clinical development of nemvaleukin alfa following a review of clinical trial data, reduce its workforce by approximately 90% and commence the exploration of strategic alternatives focused on maximizing shareholder value. In August 2025, Mural and XOMA Royalty Corporation…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.1B$1.7B$1.6B$1.5B
Net income−$158.3M$355.8M$367.1M$241.7M
Operating cash flow$21.0M$401.4M$439.1M$520.8M
Free cash flow−$17.2M$353.3M$405.6M$480.3M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$1.5B ▼ 5.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

7 filings in the last 30 days · SEC EDGAR

All filings
2 more

About the company

Alkermes plc., Dublin 4, L2 · from the 10-K filed Feb 25, 2026

The following discussion contains forward-looking statements. Actual results may differ significantly from those expressed or implied in the forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements” on page 3 of this Annual Report. Factors that might cause future results to differ materially from those expressed or implied in the forward-looking statements include, but are not limited to, those discussed in “Item 1A - Risk Factors” and elsewhere in this Annual Report.

Headquarters
Dublin 4, L2
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 3, 2026

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 12, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALKS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.